Q2 25 EPS
$0.75
BEAT +3.42%
Est. $0.73
Q2 25 Revenue
$5.06B
BEAT +3.39%
Est. $4.89B
vs S&P Since Q2 25
-61.1%
TRAILING MARKET
BSX -47.5% vs S&P +13.6%
Market Reaction
Did BSX Beat Earnings? Q2 2025 Results
Boston Scientific delivered a standout second quarter, posting adjusted EPS of $0.75 against a consensus estimate of $0.73, a beat of 3.42%, while revenue of $5.06 billion topped the $4.89 billion estimate by 3.39% and grew 22.8% year over year. The … Read more Boston Scientific delivered a standout second quarter, posting adjusted EPS of $0.75 against a consensus estimate of $0.73, a beat of 3.42%, while revenue of $5.06 billion topped the $4.89 billion estimate by 3.39% and grew 22.8% year over year. The primary engine behind the quarter was the Cardiovascular segment, which surged 26.8% on a reported basis, driven by Cardiology growth of 29.3% and bolstered by FDA approval to expand the FARAPULSE PFA System labeling to include persistent atrial fibrillation, a key regulatory catalyst that reinforced the company's position in cardiac rhythm management. MedSurg contributed meaningfully as well, with Urology alone advancing 28.9%. Geographically, U.S. Growth of 30.7% led all regions. With momentum firmly in hand, Boston Scientific raised its full-year 2025 outlook to 18 to 19 percent reported growth and adjusted EPS of $2.95 to $2.99, while guiding Q3 adjusted EPS to $0.70 to $0.72, signaling continued confidence in the durability of its growth trajectory.
Key Takeaways
- • Exceptional Cardiovascular segment growth of 26.8%, driven by Cardiology (29.3%) and Peripheral Interventions (18.3%)
- • U.S. sales growth of 30.7% year-over-year
- • Urology business grew 28.9% on a reported basis
- • Organic net sales growth of 17.4%, significantly exceeding guidance of 13 to 15 percent
- • Margin expansion alongside investment prioritization for future growth
BSX YoY Financials
Q2 2025 vs Q2 2024, source: SEC Filings
BSX Revenue by Segment
With YoY comparisons, source: SEC Filings
BSX Revenue by Geography
With YoY comparisons, source: SEC Filings
“This was another excellent quarter — marked by exceptional top-line performance — that delivered margin expansion and prioritized investment for future growth.”
— Mike Mahoney, Q2 2025 Earnings Press Release
BSX Earnings Trends
BSX vs Market 30 Day Price Reactions
30-day stock return vs benchmark after each earnings
BSX EPS Trend
Earnings per share: estimate vs actual
BSX Revenue Trend
Quarterly revenue: estimate vs actual
BSX Quarterly Results
5 quarters of earnings data
| Quarter | EPS Est. | EPS Act. | Surprise | Revenue | Rev. Surprise |
|---|---|---|---|---|---|
| Q1 26 | — | $0.80 | — | $5.20B | +0.60% |
| Q4 25 BEAT FY | $0.78 | $0.80 | +2.56% | $5.29B | +0.04% |
| FY Full Year | $3.04 | $3.06 | +0.80% | $20.07B | +0.01% |
| Q3 25 BEAT | $0.71 | $0.75 | +5.09% | $5.07B | +1.83% |
| Q2 25 BEAT | $0.73 | $0.75 | +3.42% | $5.06B | +3.39% |
| Q1 25 BEAT | $0.67 | $0.75 | +11.52% | $4.66B | +1.98% |